Antipsychotic medication adherence and satisfaction among Palestinian people with schizophrenia

Current Clinical Pharmacology

Volumn 7, Issue 1, 2012, Pages 49-55

  Sweileh, Waleed M ^a   Ihbesheh, Manal S ^a   Jarar, Ikhlas S ^a   Sawalha, Ansam F ^a   Taha, Adham S Abu ^a   Zyoud, Sa'ed H ^b   Morisky, Donald E ^c  

^a AN NAJAH NATIONAL UNIVERSITY   (Palestine)

^b SCHOOL OF PHYSICS   (Malaysia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Medication adherence; Palestine; Schizophrenia; Treatment satisfaction

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; ARABS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ISRAEL; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84857129304     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488412799218761     Document Type: Article

References (63)

1. Palmer BW, Heaton RK, Gladsjo JA, et al. Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. Schizophr Res 2002; 55(3): 205-15.
2. Pinikahana J, Happell B, Hope J, Keks NA. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. Int J Ment Health Nurs 2002; 11(2): 103-11.
3. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003; 26(1): 25-40.
4. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004; 18(13): 877-93.
5. Campbell M, Young PI, Bateman DN, Smith JM, Thomas SH. The use of atypical antipsychotics in the management of schizophrenia. Br J Clin Pharmacol. 1999; 47(1): 13-22.
6. Damen J, Thuresson PO, Heeg B, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic. medications. Appl Health Econ Health Policy 2008; 6(4): 189-97.
7. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatr 2002; 159(1): 103-8.
8. Byrne MK, Deane FP, Caputi P. Mental health clinicians' beliefs about medicines, attitudes, and expectations of improved medication adherence in patients. Eval Health Prof 2008; 31(4): 390-403.
9. Gibson TB, Jing Y, Kim E, et al. Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients. Manag Care 2010; 19(8): 40-7.
10. Svestka J, Bitter I. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders. Neuro Endocrinol Lett 2007; 28(Suppl 1): 95-116.
11. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications]. Encephale 2002; 28(3 Pt 1): 266-72.
12. Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006; 1(1): 47-56.
13. Tibaldi G, Salvador-Carulla L, Garcia-Gutierrez JC. From treatment adherence to advanced shared decision making: new professional strategies and attitudes in mental health care. Curr Clin Pharmacol 2011; 6(2): 91-9.
14. Lanouette NM, Folsom DP, Sciolla A, Jeste DV. Psychotropic medication nonadherence among United States Latinos: a comprehensive literature review. Psychiatr Serv 2009; 60(2): 157-74.
15. Borras L, Mohr S, Brandt PY, Gillieron C, Eytan A, Huguelet P. Religious beliefs in schizophrenia: their relevance for adherence to treatment. Schizophr Bull 2007; 33(5): 1238-46.
16. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 2003; 37(5): 625-30.
17. Bussing A, Abu-Hassan WM, Matthiessen PF, Ostermann T. Spirituality, religiosity, and dealing with illness in Arabic and German patients. Saudi Med J 2007; 28(6): 933-42.
18. Shah R, Kulhara P, Grover S, Kumar S, Malhotra R, Tyagi S. Relationship between spirituality/religiousness and coping in patients with residual schizophrenia. Qual Life Res 2011; 20(7): 1053-60.
19. Kadri N, Manoudi F, Berrada S, Moussaoui D. Stigma impact on Moroccan families of patients with schizophrenia. Can J Psychiatr 2004; 49(9): 625-9.
20. Phillips MR, Pearson V, Li F, Xu M, Yang L. Stigma and expressed emotion: a study of people with schizophrenia and their family members in China. Br J Psychiatr 2002; 181: 488-93.
21. Tsang HW, Fung KM, Chung RC. Self-stigma and stages of change as predictors of treatment adherence of individuals with schizophrenia. Psychiatry Res 2010; 180(1): 10-5.
22. Fung KM, Tsang HW, Chan F. Self-stigma, stages of change and psychosocial treatment adherence among Chinese people with schizophrenia: a path analysis. Soc Psychiatr Psychiatr Epidemiol 2010; 45(5): 561-8.
23. Fung KM, Tsang HW, Corrigan PW. Self-stigma of people with schizophrenia as predictor of their adherence to psychosocial treatment. Psychiatr Rehabil J 2008; 32(2): 95-104.
24. McAuley JW, McFadden LS, Elliott JO, Shneker BF. An evaluation of self-management behaviors and medication adherence in patients with epilepsy. Epilepsy Behav 2008; 13(4): 637-41.
25. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67-74.
26. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes 2009; 7: 36.
27. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction. Questionnaire for Medication (TSQM), using a national panel. study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
28. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005; 8(Suppl 1): S9-S24.
29. Overall J, Gorham D. The brief psychiatric rating scale. Psychol Rep 1962; 10(3): 799-812.
30. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 21: 97-9.
31. Lukoff D, Liberman RP, Nuechterlein KH. Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophr Bull 1986; 12(4): 578-602.
32. Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale: The drift busters. Intl J Methods Psychiatric Res 1993; 3: 221-24.
33. Ruggeri M, Koeter M, Schene A, et al. Factor solution of the BPRS-expanded version in schizophrenic outpatients living in five European countries. Schizophr Res 2005; 75(1): 107-17.
34. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47(6): 716-9.
35. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23(4): 637-51.
36. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatr Law 1986; 14(2): 105-22.
37. Zahid MA, Ohaeri JU. Relationship of family caregiver burden with quality of care and psychopathology in a sample of Arab subjects with schizophrenia. BMC Psychiatry 2010; 10: 71.
38. Breen A, Swartz L, Joska J, Flisher AJ, Corrigall J. Adherence to treatment in poorer countries: a new research direction? Psychiatr Serv 2007; 58(4): 567-8.
39. Swami V, Furnham A, Kannan K, Sinniah D. Beliefs about schizophrenia and its treatment in Kota Kinabalu, Malaysia. Int J Soc Psychiatr 2008; 54(2): 164-79.
40. Sheikh S, Furnham A. A cross-cultural study of mental health beliefs and attitudes towards seeking professional help. Soc Psychiatry Psychiatr Epidemiol 2000; 35(7): 326-34.
41. Neeleman J, King MB. Psychiatrists' religious attitudes in relation to their clinical practice: a survey of 231 psychiatrists. Acta Psychiatr Scand 1993; 88(6): 420-4.
42. Lukoff D, Lu FG, Turner R. Cultural considerations in the assessment and treatment of religious and spiritual problems. Psychiatr Clin North Am 1995; 18(3): 467-85.
43. Fujikawa M, Togo T, Yoshimi A, et al. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatr 2008; 32(3): 755-60.
44. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatr 2004; 65(10): 1372-6.
45. Watanabe A, Shibata I, Kato T. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. Psychiatry Clin Neurosci 2004; 58(3): 268-73.
46. Gharabawi GM, Greenspan A, Rupnow MF, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry 2006; 6: 45.
47. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatr 2004; 65(7): 932-9.
48. Maneesakorn S, Robson D, Gournay K, Gray R. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs 2007; 16(7): 1302-12.
49. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 2009; 35(2): 336-46.
50. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatr 2009; 70(7): 990-6.
51. Meier J, Becker T, Patel A, et al. Effect of medication-related factors on adherence in people with schizophrenia: a European multi-centre study. Epidemiol Psichiatr Soc 2010; 19(3): 251-9.
52. Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatr 2000; 61(5): 382-6.
53. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 2006; 144(2-3): 177-89.
54. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51(2): 216-22.
55. Cabeza IG, Amador MS, Lopez CA, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000; 41(2): 349-55.
56. Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003; 19(7): 619-26.
57. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatr 2006; 63(10): 1079-87.
58. Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009; 25(9): 2197-206.
59. Gutierrez-Casares JR, Canas F, Rodriguez-Morales A, Hidalgo-Borrajo R, Alonso-Escolano D. Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. CNS Spectr 2010; 15(5): 327-37.
60. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl 2009; 52: S20-8.
61. Vehof J, Postma MJ, Bruggeman R, et al. Predictors for starting depot administration of risperidone in chronic users of antipsychotics. J Clin Psychopharmacol 2008; 28(6): 625-30.
62. Jamous RM, Sweileh WM, Abu-Taha AS, Sawalha AF, Zyoud SH, Morisky DE. Adherence and satisfaction with oral hypoglycemic medications: a pilot study in Palestine. Int J Clin Pharm 2011.
63. Sweileh WM, Ihbesheh MS, Jarar IS, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 2011; 21(3): 301-5.